Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temper...
Comprehensive, easy-to-understand information about this condition
How we create this content →Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Connect with organizations supporting the autoimmune hemolytic anemia, warm type community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about autoimmune hemolytic anemia, warm type
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning autoimmune hemolytic anemia, warm type
Updated Feb 9, 2026
Sanofi's rilzabrutinib receives FDA Breakthrough Therapy designation and orphan drug status in Japan for warm autoimmune hemolytic anemia. This recognition accelerates the development of the treatment for this rare condition.
Sanofi's rilzabrutinib has received breakthrough therapy designation in the US and orphan drug status in Japan for treating warm autoimmune hemolytic anemia (wAIHA). This rare blood disorder involves the destruction of red blood cells, and rilzabrutinib is a novel oral Bruton’s tyrosine kinase inhibitor.